Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10199616rdf:typepubmed:Citationlld:pubmed
pubmed-article:10199616lifeskim:mentionsumls-concept:C0027882lld:lifeskim
pubmed-article:10199616lifeskim:mentionsumls-concept:C1706383lld:lifeskim
pubmed-article:10199616lifeskim:mentionsumls-concept:C0013030lld:lifeskim
pubmed-article:10199616lifeskim:mentionsumls-concept:C0001443lld:lifeskim
pubmed-article:10199616lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:10199616lifeskim:mentionsumls-concept:C0085940lld:lifeskim
pubmed-article:10199616lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:10199616lifeskim:mentionsumls-concept:C1521805lld:lifeskim
pubmed-article:10199616pubmed:issue3lld:pubmed
pubmed-article:10199616pubmed:dateCreated1999-7-7lld:pubmed
pubmed-article:10199616pubmed:abstractTextThe impulse flow-dependent dopamine release in the striatum was acutely blocked by unilateral lesion of the medial forebrain bundle with 6-hydroxydopamine. Within 45 min this disruption reduced the striatal extracellular dopamine levels by 80% as determined by in vivo voltammetry. A strong induction of c-fos messenger RNA was detected in the ipsilateral dorsolateral striatum 75 min after 6-hydroxydopamine injection by in situ hybridization. Double labelling demonstrates that this induction was confined to neurons expressing the dopamine D2 receptor messenger RNA. At this time-point, there were no changes in the striatal levels of either tyrosine hydroxylase immunoreactivity or dopamine D2 receptor messenger RNA. The c-fos messenger RNA expression induced by acute 6-hydroxydopamine injection was abolished by intraperitoneal pretreatment with the dopamine D2 receptor agonist, quinelorane (2 mg/kg) and strongly reduced by administration of the selective adenosine A2A receptor antagonist SCH-58261 (5 mg/kg). The results reported here show, by using a novel methodological approach, that an acute decrease of dopamine release causes an induction of c-fos messenger RNA in dopamine D2 receptor-containing striatopallidal neurons. This, together with previous findings, demonstrates that the c-fos gene expression is tonically inhibited by the impulse flow-dependent dopamine release via D2 receptors. In addition, this study provides evidence that endogenous adenosine, acting via adenosine A2A receptors, induces striatal c-fos messenger RNA when extracellular dopamine levels are strongly reduced. Thus endogenous dopamine and adenosine exert opposite effects on the activity of the D2-containing striatopallidal neurons.lld:pubmed
pubmed-article:10199616pubmed:languageenglld:pubmed
pubmed-article:10199616pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:citationSubsetIMlld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199616pubmed:statusMEDLINElld:pubmed
pubmed-article:10199616pubmed:monthMarlld:pubmed
pubmed-article:10199616pubmed:issn0306-4522lld:pubmed
pubmed-article:10199616pubmed:authorpubmed-author:FredholmB BBBlld:pubmed
pubmed-article:10199616pubmed:authorpubmed-author:BlochBBlld:pubmed
pubmed-article:10199616pubmed:authorpubmed-author:GonorJJlld:pubmed
pubmed-article:10199616pubmed:authorpubmed-author:Le MoineCClld:pubmed
pubmed-article:10199616pubmed:authorpubmed-author:SvenningssonP...lld:pubmed
pubmed-article:10199616pubmed:authorpubmed-author:FourreauLLlld:pubmed
pubmed-article:10199616pubmed:issnTypePrintlld:pubmed
pubmed-article:10199616pubmed:volume89lld:pubmed
pubmed-article:10199616pubmed:ownerNLMlld:pubmed
pubmed-article:10199616pubmed:authorsCompleteYlld:pubmed
pubmed-article:10199616pubmed:pagination827-37lld:pubmed
pubmed-article:10199616pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:meshHeadingpubmed-meshheading:10199616...lld:pubmed
pubmed-article:10199616pubmed:year1999lld:pubmed
pubmed-article:10199616pubmed:articleTitleOpposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons.lld:pubmed
pubmed-article:10199616pubmed:affiliationDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.lld:pubmed
pubmed-article:10199616pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10199616pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10199616pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10199616lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10199616lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10199616lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10199616lld:pubmed